Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
暂无分享,去创建一个
C. Carroll | E. Kaltenthaler | R. Dickson | D. Papaioannou | A. Boland | E Kaltenthaler | Patrick E B. Fitzgerald | A Boland | D Papaioannou | P Fitzgerald | R Dickson | P. Fitzgerald | C Carroll | Chris Carroll
[1] E. Loveman,et al. Ustekinumab for the treatment of moderate to severe psoriasis. , 2009, Health Technology Assessment.
[2] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[3] 王林,et al. CONSORT , 2011 .
[4] G. Mowatt,et al. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. , 2009, Health technology assessment.
[5] Y. Dundar,et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy , 2011, PharmacoEconomics.
[6] 黄亚明(整理),et al. ICMJE , 2012 .
[7] A. Ogata,et al. Tocilizumab for the treatment of rheumatoid arthritis , 2010, Expert review of clinical immunology.
[8] S. Tubeuf,et al. Cetuximab for the first-line treatment of metastatic colorectal cancer. , 2010, Health technology assessment.
[9] D. Hinds,et al. Varenicline for Smoking Cessation: Nausea Severity and Variation in Nicotinic Receptor Genes , 2011, The Pharmacogenomics Journal.
[10] L. Spencer,et al. Qualitative data analysis for applied policy research , 2002 .
[11] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[12] S. Locarnini,et al. Entecavir for the treatment of chronic hepatitis B , 2004, Expert review of anti-infective therapy.
[13] A. Roman-Urrestarazu. Pemetrexed for the first-line treatment of non-small-cell lung cancer , 2009 .
[14] M. Stevenson,et al. Febuxostat for the Management of Hyperuricaemia in Patients with Gout , 2011, PharmacoEconomics.
[15] J. Shepherd,et al. Omalizumab for the treatment of severe persistent allergic asthma. , 2009, Health Technology Assessment.
[16] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[17] Sue Ziebland,et al. Analysing qualitative data , 2000, BMJ : British Medical Journal.
[18] M. Boysen,et al. Erlotinib for the treatment of non-small-cell lung cancer. , 2009, The Lancet. Oncology.
[19] Fiona A Miller,et al. Incorporating documents into qualitative nursing research. , 2005, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.
[20] Feros Pm. The Pharmaceutical Benefits Scheme. , 1986, The Medical journal of Australia.
[21] A D Oxman,et al. Systematic Reviews: Checklists for review articles , 1994, BMJ.